Literature DB >> 15474727

Quantifying the impact of hepatitis A immunization in the United States, 1995-2001.

Taraz Samandari1, Beth P Bell, Gregory L Armstrong.   

Abstract

Hepatitis A rates have declined to historically low rates in the United States. To assess the degree to which this decline was attributable to immunization, we correlated changes in the incidence of hepatitis A with increases in immunization coverage in a Poisson regression model. In a model allowing for herd immunity, an estimated 97,800 hepatitis A cases were averted due to immunization between 1995-2001, including 39% of potential cases in 2001. Assuming no herd immunity; 32,300 cases of hepatitis A would have been prevented. Sensitivity analysis showed that the number of averted cases in this period could range from 45,500 to 172,900. Among children 2-18 years old, vaccination coverage averaged 10% in 2001 and is estimated to have prevented 51% of cases in this age group. These results suggest that much of the recent reduction of hepatitis A rates is attributable to immunization and that immunization has been associated with a strong herd immunity effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474727     DOI: 10.1016/j.vaccine.2004.04.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis.

Authors:  Eduardo Lopez; Roberto Debbag; Laurent Coudeville; Florence Baron-Papillon; Judith Armoni
Journal:  J Gastroenterol       Date:  2007-03-12       Impact factor: 7.527

Review 2.  Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases.

Authors:  Emmet B Keeffe
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

Review 3.  Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Authors:  Andrea M Anonychuk; Andrea C Tricco; Chris T Bauch; Ba' Pham; Vladimir Gilca; Bernard Duval; Ava John-Baptiste; Gloria Woo; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Determinants of anti-hepatitis A antibody seroprevalence in 2- to 19-year-olds in the USA using NHANES 2007-2008.

Authors:  E Velasco-Mondragon; I Lindong; F Kamangar
Journal:  Epidemiol Infect       Date:  2011-05-09       Impact factor: 2.451

5.  Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China.

Authors:  Zhuang Fangcheng; Wang Xuanyi; Chen Mingding; Jiang Liming; Wu Jie; Jiang Qi; Gong Yuanping; Qian Wen; Xin Yajuan; Mao Jiangsen
Journal:  Hepat Mon       Date:  2012-02-29       Impact factor: 0.660

6.  Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A.

Authors:  Arni S R Srinivasa Rao; Maggie H Chen; Ba' Z Pham; Andrea C Tricco; Vladimir Gilca; Bernard Duval; Murray D Krahn; Chris T Bauch
Journal:  BMC Infect Dis       Date:  2006-12-05       Impact factor: 3.090

Review 7.  Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review.

Authors:  Ba' Pham; Bernard Duval; Gaston De Serres; Vladimir Gilca; Andrea C Tricco; Jan Ochnio; David W Scheifele
Journal:  BMC Infect Dis       Date:  2005-07-07       Impact factor: 3.090

Review 8.  Hepatitis B and A vaccination in HIV-infected adults: A review.

Authors:  G Mena; A L García-Basteiro; J M Bayas
Journal:  Hum Vaccin Immunother       Date:  2015-07-24       Impact factor: 3.452

9.  The United States and Canada as a coupled epidemiological system: an example from hepatitis A.

Authors:  Raluca Amariei; Allan R Willms; Chris T Bauch
Journal:  BMC Infect Dis       Date:  2008-02-28       Impact factor: 3.090

10.  Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study.

Authors:  Angela Domínguez; Miquel Bruguera; Pere Plans; Jordi Espuñes; Josep Costa; Antoni Plasencia; Lluis Salleras
Journal:  BMC Infect Dis       Date:  2007-07-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.